SUNITINIB MSN 12,5 mg Rumānija - rumāņu - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sunitinib msn 12,5 mg

pharmadox healthcare limited - malta - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

SUNITINIB MSN 25 mg Rumānija - rumāņu - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sunitinib msn 25 mg

pharmadox healthcare limited - malta - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

SUNITINIB MSN 37,5 mg Rumānija - rumāņu - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sunitinib msn 37,5 mg

pharmadox healthcare limited - malta - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

SUNITINIB MSN 50 mg Rumānija - rumāņu - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sunitinib msn 50 mg

pharmadox healthcare limited - malta - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza

Tagrisso Eiropas Savienība - rumāņu - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - carcinom, pulmonar non-celulă mică - alte medicamente antineoplazice, inhibitori de proteinkinază - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Mitoxantron-BP 2 mg/ml concentrat pentru soluţie perfuzabilă Moldova - rumāņu - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

mitoxantron-bp 2 mg/ml concentrat pentru soluţie perfuzabilă

sc balkan pharmaceuticals srl - mitoxantronum - concentrat pentru soluţie perfuzabilă - 2 mg/ml